Abstract: A lid 20 is a paper lid capable of adhering to a flange portion of a container body and includes: a tab 25; back half-cut lines 35a, 36a extending from the tab 25 outward and away from each other at an acute angle with respect to a paper grain direction K; back half-cut lines 37a, 38a extending from the outer ends of the back half-cut lines 35a, 36a, respectively, along the paper grain direction K; front half-cut lines 35b, 36b located on the outer side of the back half-cut lines 35a, 36a with a width W between the front and back half-cut lines and extending along the back half-cut lines 35a, 36a at an acute angle with respect to the paper grain direction K; and front half-cut lines 37b, 38b located on the outer side of the back half-cut lines 37a, 38a with the width W between the front and back half-cut lines and extending along the back half-cut lines 37a, 38a and the paper grain direction K.

Abstract: [Object] To achieve biometric authentication that is excellent in convenience and has high accuracy.

Abstract: A lid 20 is a paper lid capable of adhering to a flange portion of a container body and includes: a tab 25; back half-cut lines 35a, 36a extending from the tab 25 outward and away from each other at an acute angle with respect to a paper grain direction K; back half-cut lines 37a, 38a extending from the outer ends of the back half-cut lines 35a, 36a, respectively, along the paper grain direction K; front half-cut lines 35b, 36b located on the outer side of the back half-cut lines 35a, 36a with a width W between the front and back half-cut lines and extending along the back half-cut lines 35a, 36a at an acute angle with respect to the paper grain direction K; and front half-cut lines 37b, 38b located on the outer side of the back half-cut lines 37a, 38a with the width W between the front and back half-cut lines and extending along the back half-cut lines 37a, 38a and the paper grain direction K.

Abstract: Disclosed is a pharmaceutical composition for antifungal use, comprising: 1) one or more compounds selected from compounds represented by the general formula (1) below and physiologically acceptable salts thereof; 2) one or more compounds selected from polypropylene glycol, diesters of dibasic acids, triacetin, 2-ethyl-1,3-hexanediol, lauromacrogol, and polyoxyethylene-polyoxypropylene glycol; and 3) one or more compounds selected from glucono-?-lactone, propylene glycol, glycerin, and lactic acid. General formula (1) (In the formula, X represents a halogen or hydrogen). wherein X represents a halogen or hydrogen.

Abstract: A shim assembly for a disk brake includes inside shim locking pieces which are provided in an inside shim main body of the inside shim plate and bent toward the pressure plate so that displacement of the inside shim plate in radial and peripheral directions is restricted and outside shim locking pieces which are provided in an outside shim main body of the outside shim plate and bent toward the pressure plate so that displacement of the outside shim plate in the peripheral direction is allowed and displacement thereof in the radial direction is restricted. Engaging pawls are provided in the inside shim main body and projected from a peripheral edge of the pressure plate. The outside shim locking pieces are respectively engaged with the engaging pawls so as to cover the engaging pawls, to prevent the outside shim plate against separation from the inside shim plate.

Abstract: Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1), 50 to 95 mass % of an alcohol such as ethanol, 0.1 to 35 mass % of water or the like, and 0.01 to 5 mass % of a cellulose thickening agent. X is a halogen or H.

Abstract: Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1), 50 to 95 mass % of an alcohol such as ethanol, 0.1 to 35 mass % of water or the like, and 0.01 to 5 mass % of a cellulose thickening agent. X is a halogen or H.

Abstract: A shim assembly for a disk brake includes inside shim locking pieces which are provided in an inside shim main body of the inside shim plate and bent toward the pressure plate so that displacement of the inside shim plate in radial and peripheral directions is restricted and outside shim locking pieces which are provided in an outside shim main body of the outside shim plate and bent toward the pressure plate so that displacement of the outside shim plate in the peripheral direction is allowed and displacement thereof in the radial direction is restricted. Engaging pawls are provided in the inside shim main body and projected from a peripheral edge of the pressure plate. The outside shim locking pieces are respectively engaged with the engaging pawls so as to cover the engaging pawls, to prevent the outside shim plate against separation from the inside shim plate.

Abstract: Disclosed is a pharmaceutical composition for antifungal use, comprising: 1) one or more compounds selected from compounds represented by the general formula (1) below and physiologically acceptable salts thereof; 2) one or more compounds selected from polypropylene glycol, diesters of dibasic acids, triacetin, 2-ethyl-1,3-hexanediol, lauromacrogol, and polyoxyethylene-polyoxypropylene glycol; and 3) one or more compounds selected from glucono-?-lactone, propylene glycol, glycerin, and lactic acid. General formula (1) (In the formula, X represents a halogen or hydrogen). wherein X represents a halogen or hydrogen.

Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.

Abstract: Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1) below, 50-95% by mass of an alcohol, and 0.1-35% by mass of water and/or an anionic surfactant.

Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.

Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.

Abstract: Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1) below, 50-95% by mass of an alcohol, and 0.1-35% by mass of water and/or an anionic surfactant.

Abstract: A Cancer radiotherapeutic method using 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole (compound (i), and creatinine in an amount of 0.001 to part by mass with respect to 1 part by mass of compound (1); and irradiation.

Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.

Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.

Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.

Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.